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CASE REPORTSStarr–Edwards aortic valve: Forty-four years old and still working!Pankaj Saxena, FRACS, PhD,a Crystal R. Bonnichsen, MD,b and Kevin L. Greason, MD,a Rochester, MinnThe Starr–Edwards valve (Edwards Lifesciences, Irvine,
Calif) was first introduced in clinical practice approxi-
mately 50 years ago.1 Since then, more than 200,000
implants of this valve have been performed worldwide.2
We highlight the durability of the valve in this case report
of a patient with a functioning Starr–Edwards aortic valve
implanted more than 44 years ago.
CLINICAL SUMMARY
A 66-year-old man presented to the Mayo Clinic with a
7-cm ascending aortic aneurysm and symptomatic
2-vessel coronary artery disease (Figure 1, A and B). The
patient previously had total correction of tetralogy of Fallot
and aortic valve replacement with a 26-mm Starr–Edwards
valve at 22 years of age at the Mayo Clinic. During the cur-
rent evaluation, echocardiography demonstrated an ejection
fraction of 45%, a mean systolic Doppler gradient across
the valve prosthesis of 30 mm Hg, and mild to moderate
prosthetic valvular regurgitation (Figure 1, C).
The patient underwent a successful operation that
included redo sternotomy, bicaval and aortic cannulation,
and myocardial protection with antegrade and retrograde
cold blood cardioplegia. We performed coronary artery
bypass graft revascularization to the left anterior descending
and obtuse marginal coronary arteries, replacement of theFIGURE 1. A, Chest x-ray (posterior-anterior) view shows Starr–Edwards va
shows large ascending aortic aneurysm. C, Intraoperative transesophageal echoc
the prosthetic aortic valve. D, Explanted valve prothesis from the aortic aspect
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The Journal of Thoracic and CaStarr–Edwards valve with a composite valve conduit of a
25-mm Carbomedics Top-Hat valve (Sorin Group, Milan,
Italy) and 30-mm polyester graft, and hemi-arch replace-
ment of the aorta under deep hypothermic circulatory arrest.
Examination of the Star–Edwards valve demonstrated a
mild degree of pannus growth over the sewing ring of the
prosthetic valve (Figure 1, D) but no major structural valve
deterioration. The patient had an uncomplicated postopera-
tive course and was discharged on postoperative day num-
ber 5. Pathologic examination of the aorta showed cystic
medial degeneration. The patient was in New York Heart
Association functional class II at 5 weeks of follow-up
with a normally functioning prosthetic valve.DISCUSSION
Surgical treatment of heart valve disease was revolution-
ized by the introduction of the Starr–Edwards ball and cage
valve model in the 1960s. Clinical follow-up of more than
30 years with this valve has been satisfactory.2-4 Our
patient was asymptomatic up to 1 year ago when he
presented with angina. His most recent cardiovascular
evaluation was 10 years before clinical presentation.
There were no bleeding or thromboembolic complications
related to his prosthetic aortic valve.CONCLUSIONS
We report the 44-year follow-up of a patient who had
aortic valve replacement with the Starr–Edwards valve
without any significant valvular dysfunction or thromboem-
bolic complications. Although Starr–Edwards valves have
largely been replaced in clinical practice by other mechan-
ical valves, they may still provide ultralong-term durability
in patients who underwent operation in an earlier era.lve (Edwards Lifesciences, Irvine, Calif) in aortic position. B, Aortogram
ardiogram in long axis with color Doppler shows mild regurgitation across
with functional ball and cage mechanism.
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Valve Dis. 2012;21:679-81.A complicated case of Carney complex: Fifth reoperative cardiac
surgery for resection of recurrent cardiac myxomaManuel Wilbring, MD,a Stephan Wiedemann, MD,b Utz Kappert, MD,a and Klaus Matschke, MD,a
Dresden, GermanyCarney complex is a rare genetic disorder that was first
described by Carney and colleagues1 in 1985. It is mainly
characterized by cardiac myxoma, spotty pigmentation
and endocrine hyperactivity. In approximately 50% of the
affected patients, a heterozygous mutation of the protein
kinase A regulatory subunit 1 gene (PRKAR1A) can be
found. The mutation, which is usually localized on the
long arm of chromosome 17 (17q22–q24), is named
CC-Type 1. In CC-Type 2, the mutation can be found on
chromosome 2 (2p16). The heredity is autosomal dominant
with variable penetrance. There exist no clinical differences
between genetic carriers and noncarriers.2CLINICAL SUMMARY
In 2012, a 60-year-old female patient with Carney
complex and history of previous 4 cardiac operations for
recurrent myxoma was seen for elective echocardiographic
control. The previous control by magnetic resonance
imaging (MRI) 5 months previously had been unremarkable
(Figure 1, A).
In 1988, 1991, 2002, and 2008 she had already undergone
cardiac surgery for resection of cardiac myxoma at different
localizations. Further clinical signs of Carney complex
were recurrent mucosal tumors since her earliest childhood,
spotty pigmentation, hirsutism, syndactyly of the toes,
kyphosis, hyperthyroidism, and an adenoma of the pituitary
gland. The patient also had a history of peripheral arterialembolism and occlusion of superficial femoral artery. As
demonstrated in the family tree in Figure 2, the patient
was the only one in her family affected by clinical signs
of Carney complex. Genetic examination of her family
has not been performed to date.
MRI and echocardiography revealed a new intracardiac
tumor-formation in the left ventricle affecting the mitral
annulus (Figure 1, A–C). Cardiac surgery was performed
through a median sternotomy and with common aortic can-
nulation. For venous cannulation, a 2-stage cannula was
used. The procedure was performed in normothermia. Intra-
operatively, the myxoma was resected (Figure 1, D).
Because of the involvement of the mitral annulus and
the need for radical resection, biologic mitral valve
replacement was also performed. The intraoperative and
postoperative courses were uneventful. Predischarge
echocardiography revealed good prosthetic function.
Histopathologic examination identified the tumor as a
myxoma. The patient was dismissed from the hospital on
postoperative day 6.
DISCUSSION
Carney complex is a rare genetic disorder.1,3 This patient
demonstrated all the typical signs of Carney complex
including myxoma, spotty pigmentation, endocrine
hyperactivity, and cutaneous tumors. As is typical with
complications of cardiac tumors, the patient also had a
history of peripheral arterial embolism and occlusion of
superficial femoral artery. In contrast with other reported
cases, a specific characteristic of the present case was the
fifth recurrence of myxoma, each time at a different
location.4,5 The reported patient is the sole person
affected by Carney complex in her family. This might be
explained by the variable penetrance of the autosomal
dominant genetic disorder. Her fifth reoperative cardiac
surgical procedure could be performed without any
procedural morbidity, despite strong pericardial
adhesions. Worth mentioning is the fact that MRI controlery c October 2013
